| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2017: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to develop a new technology for utilizing transgenic chickens as a bioreactor for the production of biopharmaceuticals at low cost. Previously, we developed avian embryo culture method, high-efficiency gene transfer using viral vector, and oviduct-specific gene expression system, and successfully generated transgenic chickens and quails that produce recombinant proteins such as antibodies in eggs and body tissues. In this research, we have developed a platform technology for biopharmaceutical production using transgenic chickens by fusing the genome editing technology, which has made remarkable progress in recent years, with the cell engineering technology we developed.
|
